BIM
MACK

Bogle Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bogle Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-84,519
Closed -$681K – 442
2017
Q4 		$681K Buy
+84,519
New +$788K 0.05% 232

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bogle Investment Management's MACK Position: Q1 2018 in Review

Bogle Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2018, closing a stake of 84,519 shares — an estimated $681K sold.

Bogle Investment Management first reported a position in MACK in Q4 2017 and held it in 1 quarter. The position peaked at $681K in Q4 2017. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

  • Bogle Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Bogle Investment Management sold 84,519 Merrimack Pharmaceuticals, Inc. shares in Q1 2018, an estimated $681K.
  • Bogle Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Bogle Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $681K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Bogle Investment Management's 13F filing for Q1 2018, filed 14 May 2018.